Citations

Showing 10 of 108094 citations.

Neonatal familial hemophagocytic lymphohistiocytosis diagnosed with ultrarapid whole‐genome sequencing
Greenmyer, Jacob R. , Thompson, Whitney S. , Mavis, Stephanie C. , Hassan, Sara , Weckwerth, Jody , Hobbs, Charlotte A. , James, Kiely N. , Nahas, Shareef , Galardy, Paul J. , Collura, Christopher A. , Mavis, Stephanie, Galardy, Paul, Collura, Christopher, Thompson, Whitney S

Mayo Clinic

Pediatric Blood & Cancer | July 7, 2022 | Volume: 70 | Issue: 1 | Pages: No page available

10.1002/pbc.29871 | PMID 35796407 Get It

Inflammatory biomarkers, multi-morbidity, and biologic aging
Rocca, Walter A. , Jacobson, Debra J., McGree, Michaela E. , St Sauver, Jennifer L , Rocca, Walter, LeBrasseur, Nathan, Chamberlain, Alanna, Jacobson, Debra, McGree, Michaela, Mielke, Michelle, Sauver, Jennifer L. St. , LeBrasseur, Nathan K. , Chamberlain, Alanna M. , Olson, Janet E. , Mielke, Michelle M.

Mayo Clinic

Journal of International Medical Research | July 7, 2022 | Volume: 50 | Issue: 7 | Pages: No page available

10.1177/03000605221109393 | PMID 35796512 Get It

Objectives To study the association between multi-morbidity percentiles, which is a measure of clinical aging, and interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-α. Methods Participants 50 to 95 years of age from the Mayo Clinic Study of Aging were assigned age- and sex-specific multi-morbidity percentiles using look-up tables that were reported previously (n = 1646). Percentiles were divided into quintiles for analysis. Plasma IL-6, IL-10, and TNF-α levels were measured in 1595 participants. Median inflammatory marker levels were compared across multi-morbidity quintiles using nonparametric tests. Results People with higher multi-morbidity percentiles had significantly higher IL-6 and TNF-α levels compared with those with lower multi-morbidity percentiles. Tests for trend across five multi-morbidity quintiles were significant among women for IL-6 and among participants 70 years of age or older for IL-6 and TNF-α. IL-10 was not associated with multi-morbidity percentiles. Conclusions Multi-morbidity percentiles may be a useful clinical index of biological age for future studies, particularly in women and people 70 years of age and older.
Augmenting Osteochondral Autograft Transplantation and Bone Marrow Aspirate Concentrate with Particulate Cartilage Extracellular Matrix Is Associated With Improved Outcomes
Drakos, Mark C. , Hansen, Oliver B. , Eble, Stephanie K. , Kukadia, Saanchi , Cabe, Taylor N., Kumar, Prashanth , Sofka, Carolyn M., Deland, Jonathan T. , Patel, Karan A.

Mayo Clinic

Foot & Ankle International | July 7, 2022 | Volume: 43 | Issue: 9 | Pages: 1131-1142

10.1177/10711007221104069 | PMID 35794822 Get It

Background: Osteochondral autograft transplant (OAT) is often used to treat large osteochondral lesions of the talus and is generally associated with good outcomes. The addition of adjuncts such as cartilage extracellular matrix with bone marrow aspirate concentrate (ECM-BMAC) may further improve the OAT procedure but have not been thoroughly studied. We hypothesized that the placement of ECM-BMAC around the OAT graft would improve radiographic and patient-reported outcomes following OAT. Methods: Patients who received OAT, with ECM-BMAC or BMAC alone, were screened and their charts were reviewed. For patients who did receive ECM-BMAC, the mixture was spread around the edges of the OAT plug and into any surrounding areas of cartilage damage. Survey and radiographic data were collected. Average follow-up in both groups was over 2 years. Magnetic resonance imaging scans were scored using the Magnetic Resonance Observation of Cartilage Tissue (MOCART) system. Outcomes were compared statistically between groups. Results: Patients treated with ECM-BMAC (n = 34) demonstrated significantly greater improvement of scores in the FAOS categories Symptoms (17 vs −3; P = .02) and Sports Activities (40 vs 7; P = .02), and the MOCART category Subchondral Lamina ( P = .008) compared to those treated with BMAC alone (n = 30). They also experienced significantly lower rates of postoperative cysts (53% vs 18%, P = .04) and edema (94% vs 59%, P = .02). Conclusion: The addition of ECM-BMAC to OAT was associated with improved imaging and clinical outcomes compared to OAT with BMAC alone.
Is Wrist Arthroscopy Safer with the Nanoscope?
Munaretto, Nicholas , Hinchcliff, Katharine M. , Dutton, Lauren K. , Kakar, Sanjeev , Hinchcliff, Katharine , Dutton, Lauren , Kakar, Sanjeev , Munaretto, Nicholas

Mayo Clinic

Journal of Wrist Surgery | July 6, 2022 | Volume: 11 | Issue: 05 | Pages: 450-455

10.1055/s-0042-1750179 | PMID 36339076 Get It

Abstract Background Nanoscope, given its smaller size, may be safer when establishing dorsal wrist arthroscopy portals compared with the traditional 2.7 mm arthroscope. Case Description Ten fresh frozen cadaver specimens were utilized. Dorsal radiocarpal portals were established with the Nanoscope and calipers were used to measure the distance between the portals and the surrounding anatomical structures. The only structure that was pierced during portal placement was the dorsal sensory branch of the ulnar nerve (DSUN) in one specimen when establishing the 6U portal. Our study did not note any tendon injuries. Literature Review Traditional wrist arthroscopy may be performed with a 2.7 mm arthroscope. With its larger outer sheath cannula, this may place adjacent anatomical structures at risk of injury. Clinical Relevance During wrist arthroscopy, the Nanoscope may be safer when creating portals to underlying structures. Level of Evidence This is a Level IV study.
Clinical Reasoning: A 43-Year-Old Man With Subacute Onset of Vision Disturbances, Jaw Spasms, and Balance and Sleep Difficulties
Orozco, Emma, Guo, Yong , Chen, John J. , Dubey, Divyanshu , Howell, Bradley, Moutvic, Margaret A., Louis, Erik K. St. , Moutvic, Margaret, St Louis, Erik K, St Louis, E K , Chen, John J , Dubey, Divyanshu , McKeon, Andrew

Mayo Clinic

Neurology | July 6, 2022 | Volume: 99 | Issue: 9 | Pages: 387-392

10.1212/wnl.0000000000200950 | PMID 35794020 Get It

Thyroid Disorders and Dementia Risk
Wieland, Daniel R. , Wieland, Julia R. , Wang, Han , Chen, Yi-Huei , Lin, Ching‐Heng , Wang, Jing‐Jie , Weng, Chien‐Hsiang

Mayo Clinic

Neurology | July 6, 2022 | Volume: 99 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000200740 | PMID 35794019 Get It

Complications, Readmissions, Revisions, and Patient-reported Outcomes in Patients With Parkinson Disease Undergoing Elective Spine Surgery: A Propensity-matched Analysis
Steinle, Anthony M. , Nian, Hui , Pennings, Jacquelyn S. , Bydon, Mohamad , Asher, Anthony L. , Archer, Kristin R. , Gardocki, Raymond J. , Abtahi, Amir M. , Zuckerman, Scott L. , Stephens, Byron F.

Mayo Clinic

Spine | July 6, 2022 | Volume: 47 | Issue: 20 | Pages: 1452-1462

10.1097/brs.0000000000004401 | PMID 35796661 Get It

Study Design. Retrospective analysis on prospectively collected data. Objective. To determine the effectiveness of elective spine surgery in patients with Parkinson disease (PD). Background Context. PD has become increasingly prevalent in an aging population. While surgical treatment for degenerative spine pathology is often required in this population, previous literature has provided mixed results regarding its effectiveness. Methods. Data from the Quality Outcomes Database (QOD) was queried between April 2013 and January 2019. Three surgical groups were identified: (1) elective lumbar surgery, (2) elective cervical surgery for myelopathy, (3) elective cervical surgery for radiculopathy. Patients without PD were propensity matched against patients with PD in a 5:1 ratio without replacement based on American Society of Anesthesiology grade, arthrodesis, surgical approach, number of operated levels, age, and baseline Oswestry Disability Index, Numerical Rating Scale (NRS) extremity pain, NRS back pain, and EuroQol 5-Dimensions (EQ-5D). The mean difference was calculated for continuous outcomes (Oswestry Disability Index, NRS leg pain, NRS back pain, and EQ-5D at 3 and 12 mo after surgery) and the risk difference was calculated for binary outcomes (patient satisfaction, complications, readmission, reoperation, and mortality). Results. For the lumbar analysis, PD patients had a higher rate of reoperation at 12 months (risk difference=0.057, P=0.015) and lower mean EQ-5D score at 12 months (mean difference=−0.053, P=0.005) when compared with patients without PD. For the cervical myelopathy cohort, PD patients had lower NRS neck pain scores at 3 months (mean difference=−0.829, P=0.005) and lower patient satisfaction at 3 months (risk difference=−0.262, P=0.041) compared with patients without PD. For the cervical radiculopathy cohort, PD patients demonstrated a lower readmission rate at 3 months (risk difference=−0.045, P=0.014) compared with patients without PD. Conclusion. For the matched analysis, in general, patients with and without PD had similar patient-reported outcomes and complication, readmission, and reoperation rates. These results demonstrate that a diagnosis of PD alone should not represent a major contraindication to elective spine surgery.
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis
Fatola, Tolulope, Toure, Ahmed, Flowers, Christopher R. , Link, Brian K. , Friedberg, Jonathan W. , Cohen, Jonathon B. , Kahl, Brad S. , Lossos, Izidore S. , Martin, Peter , Link, Brian K , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Maurer, Matthew , Cerhan, James R , Luan, Danny , Nastoupil, Loretta J. , Maurer, Matthew J. , Cerhan, James R.

Mayo Clinic

Blood Advances | July 6, 2022 | Volume: 6 | Issue: 15 | Pages: 4413-4423

10.1182/bloodadvances.2022007687 | PMID 35793440 Get It

Abstract Cancer clinical trial eligibility criteria may create patient populations studied in trials that do not reflect the patient populations treated in the real-world setting. Follicular lymphoma (FL) is an indolent lymphoma with heterogeneous presentations across a broad range of individuals, resulting in many acceptable management strategies. We evaluated how first-line clinical trial eligibility criteria impacted the demographic makeup and outcomes of patients with FL for whom systemic therapy might be considered. We compared the characteristics of 196 patients with FL from a single institution to eligibility criteria from 10 first-line FL trials on clinicaltrials.gov. Next, we tabulated eligibility criteria from 24 first-line FL protocols and evaluated their impact on 1198 patients with FL with stages II to IV disease from the prospective Molecular Epidemiology Resource (MER) and Lymphoma Epidemiology of Outcomes (LEO) cohort studies. We found that 39.8% and 52.7% of patients with FL might be excluded from clinical trials based on eligibility criteria derived from clinicaltrials.gov and protocol documents, respectively. Patients excluded because of renal function, prior malignancy, and self-reported serious health conditions tended to be older. Expanding stage requirement from III-IV to II-IV, and platelet requirement from ≥150 000 to ≥75 000 increased population size by 21% and 8%, respectively, in MER and by 16% and 13%, respectively, in LEO, without impacting patient demographics or outcomes. These data suggest that management of older individuals with FL may not be fully informed by recent clinical trials. Moreover, liberalizing stage and platelet criteria might expand the eligible population and allow for quicker trial accrual without impacting outcomes.
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
Loftus, Edward V. , Baumgart, Daniel C. , Kinnucan, Jami , Connelly, Susan B. , Salese, Leonardo , Su, Chinyu , Kwok, Kenneth , Woolcott, John , Armuzzi, Alessandro , Kinnucan, Jami A., Loftus, Edward V , Gecse, Krisztina Barbara

Mayo Clinic

Inflammatory Bowel Diseases | July 6, 2022 | Volume: 29 | Issue: 5 | Pages: 744-751

10.1093/ibd/izac139 | PMID 35792493 Get It

Abstract Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Patients with inflammatory bowel disease are susceptible to Clostridium difficile infection (CDI). Here, we evaluate CDI in the tofacitinib UC clinical program. Methods Events from 4 randomized, placebo-controlled studies (phase [P] 2 or P3 induction [NCT00787202; NCT01465763; NCT01458951], P3 maintenance [NCT01458574]) and an open-label, long-term extension (OLE) study (NCT01470612), were analyzed as 3 cohorts: Induction (P2/P3 induction), Maintenance (P3 maintenance), and Overall (patients receiving tofacitinib 5 or 10 mg twice daily [BID] in P2, P3, and OLE studies; including final data from the OLE study, as of August 24, 2020). Proportions and incidence rates (unique patients with events per 100 patient-years of exposure) of CDI were evaluated. Results The overall cohort comprised 1157 patients who received ≥1 dose of tofacitinib 5 or 10 mg BID, with a total of 2814.4 patient-years of tofacitinib exposure and up to 7.8 years of treatment. A total of 82.6% of patients received predominantly tofacitinib 10 mg BID. In the induction, maintenance, and overall cohorts, 3 (2 tofacitinib treated, 1 placebo treated), 3 (all placebo treated), and 9 patients had CDI, respectively; the overall cohort incidence rate was 0.31 (95% confidence interval, 0.14-0.59). CDI were all mild–moderate in severity and resolved with treatment in 8 patients. Six of 9 patients continued tofacitinib treatment without interruption. Two patients had events reported as serious due to hospitalization. Two patients were receiving corticosteroids when the CDI occurred. Conclusion CDIs among patients with UC receiving tofacitinib were infrequent, cases were mild–moderate in severity, and most resolved with treatment.
Outcomes of a Near-peer Intern Orientation Boot Camp
Saini, Astha , Ahmed, Ahmed , Bishop, Patrick, Osman, Baraa , Khan, Hajra , Adam, Omeralfaroug, Weinberger, Jarrett J., Levine, Diane L., Ahmed, Ahmed K , Alhusain, Rashid , Minhas, Hersimren , Levine, Diane L.

Mayo Clinic

No container title available | July 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1805651/v1 Get It

Abstract Background: Interns experience challenges in their transition from medical school to residency. Orientation is traditionally delivered by faculty and administrators and often does not address the intern’s daily duties.Objectives: Address traditional orientation gaps and improve incoming interns’ experience.Methods: We identified opportunities with our intern orientation using a quality improvement methodology. Plan Do Study Act (PDSA) cycle 1 consisted of a pilot boot camp. PDSA cycle 2 was conducted over two weeks, June 9-23, 2021, at the Detroit Medical Center, in Detroit, MI. Participation was voluntary. Residents were assigned incoming interns on a 1:1 basis. Five virtual sessions were conducted addressing: daily workflow, documentation, presentation skills, and utilization of the Electronic Health Records (EHR). All participants received pre- and post-program surveys.Results: 22 rising second-year and third-year residents (26%) and 22 incoming interns (58%) participated. There was a significant improvement in the understanding of daily workflow (mean improved by 0.957, p=0.003), and most tasks associated with EHR including comfort with the sign-out process (mean improved by 1.21; p=0.002), accessing specific team lists (mean improved by 1.75, p=0.001), writing orders (mean improved by 1.41; p=0.002), composing documentation (mean improved by 1.23; p=0.001). Writing notes improved significantly (mean improved by 0.52; p=0.04). Nearly all (93.2%) stated the program effectively achieved its overall goals and believed (92.9%) the program should be continued for each incoming class of interns.Conclusion: A targeted orientation boot camp led by near peers positively impacted the intern experience improving understanding of day-to-day responsibilities and comfort utilizing the electronic health record.